Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_2
3
50%
Ph phase_1
3
50%

Phase Distribution

3

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
3(50.0%)
Phase 2Efficacy & side effects
3(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(4)
Terminated(1)
Other(1)

Detailed Status

Completed4
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
80.0%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (50.0%)
Phase 23 (50.0%)

Trials by Status

terminated117%
completed467%
unknown117%

Recent Activity

0 active trials
Showing 5 of 6
terminatedphase_1

Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia

NCT00022971
unknownphase_2

Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00014664
completedphase_2

Apolizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT00089154
completedphase_1

Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Acute Lymphoblastic Leukemia, or Acute Myeloid Leukemia

NCT00017472
completedphase_2

Monoclonal Antibody Therapy in Treating Patients With Recurrent Hodgkin's Lymphoma

NCT00055783
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT00022971Phase 1

Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia

Terminated
NCT00014664Phase 2

Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Unknown
NCT00089154Phase 2

Apolizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Completed
NCT00017472Phase 1

Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Acute Lymphoblastic Leukemia, or Acute Myeloid Leukemia

Completed
NCT00055783Phase 2

Monoclonal Antibody Therapy in Treating Patients With Recurrent Hodgkin's Lymphoma

Completed
NCT00004101Phase 1

Monoclonal Antibody Therapy in Treating Patients With Recurrent Non-Hodgkin's Lymphoma

Completed

All 6 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
6